Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine.
The immunogenicity of pneumococcal polysaccharide (PS) vaccines can be improved by conjugating PS to a polypeptide carrier that alters the immune response from T-cell independent to T-cell dependent. In order to study the influence of PS or protein antigens as inducers of cell-mediated responses, 30 adults were immunized with a 23-valent pneumococcal PS vaccine (PS-group) or an 11-valent, tetanus and diphtheria mixed carrier conjugate vaccine with (adjuvant group) or without aluminium adjuvant (nonadjuvant group). Cell-mediated responses were analyzed on days 0, 14 and 28 after vaccination by measuring lymphocyte proliferation and production of interferon (IFN)-gamma (Th1 marker) or interleukin (IL)-4 and IL-5 (Th2 markers) cytokines after in vitro stimulation with the PS and protein components of the vaccines. Tetanus and diphtheria proteins were the main inducers of lymphocyte proliferative and cytokine responses. Conjugate vaccines induced increased proliferative responses to the tetanus or diphtheria protein, but not to the PS components. In the PS-group, a lymphocyte proliferative response to protein antigens was not observed. The number of antigen-specific and nonspecific IFN-gamma-secreting cells detected by ELISPOT tended to increase in all three groups in response to protein or to PS antigen. No major differences were detected in the number of IL-4-secreting cells measured 14 and 28 days after vaccination. The conjugate vaccine with adjuvant was associated with Th2 type of activation indicated by an enhanced IL-5 secretion in response to the tetanus and diphtheria protein antigens.
Wuorimaa
T
T
National Public Health Institute, Department of Vaccines, Mannerheimintie 166, FIN-00300 Helsinki, Finland. tomi.wuorimaa@ktl.fi
Käyhty
H
H
Eskola
J
J
Bloigu
A
A
Leroy
O
O
Surcel
H M
HM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000535:Aluminum / Q000008:administration & dosage; D022422:Diphtheria-Tetanus Vaccine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015848:Interleukin-5 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008297:Male; D022242:Pneumococcal Vaccines / Q000819:agonists*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D022422:Diphtheria-Tetanus Vaccine; D015848:Interleukin-5; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate; D015847:Interleukin-4; D007371:Interferon-gamma; D000535:Aluminum